CD8A and neoplasm: Genetic or pharmacologic inhibition of PI3Kγ reprograms TAMs from a tumour‐promoting (M2‐like) to a tumour‐fighting (M1‐like) phenotype, enhancing CD8+ T cell–mediated antitumor responses and synergising with checkpoint inhibitors [29, 30].